This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Lsi Medience Corporation, Mochida Pharmaceutical Co., Ltd.. Active years: 2021.
Company Filing History:
1 out of 26 
1 out of 229 Years Active: 2021
Title: Ralf Thomae: Innovator in Sepsis Prognosis
Introduction
Ralf Thomae is a notable inventor based in Gauting, Germany. He has made significant contributions to the field of medical diagnostics, particularly in the prediction of sepsis prognosis. His innovative approach has the potential to improve patient outcomes in critical care settings.
Latest Patents
Ralf Thomae holds a patent for a method that predicts the prognosis of sepsis. This method involves measuring the sCD14-ST level in a sample, which is a superior marker compared to procalcitonin for predicting outcomes in sepsis patients. His patent represents a significant advancement in the medical field, offering a more reliable means of assessing patient prognosis.
Career Highlights
Throughout his career, Ralf Thomae has worked with prominent companies such as LSI Medience Corporation and Mochida Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in medical diagnostics and innovation.
Collaborations
Ralf Thomae has collaborated with notable professionals in his field, including Takeshi Matsuya and Yoshikazu Okamura. These collaborations have likely enriched his research and development efforts, leading to impactful innovations.
Conclusion
Ralf Thomae's work in the prediction of sepsis prognosis exemplifies the importance of innovation in healthcare. His contributions are paving the way for improved diagnostic methods that can enhance patient care and outcomes.